VIRTUAL: New Social History of Pharmacy & Pharmaceuticals Festival – Panel 8 Objects, Museums, and Names
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 3: Panel 8 "Objects, Museums, and Names".
Stay up-to-date with the latest events, including faculty presentations, career events for students and alumni, and so much more.
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 3: Panel 8 "Objects, Museums, and Names".
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 3 Invited Book Talk on "Compound Remedies: Galenic Pharmacy from the Ancient Mediterranean to New Spain".
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 3: Panel 9 "Breakthroughs and Ethics".
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 3 Invited Book Talk "OD: Naloxone and the Politics of Overdose".
Join us for Day 4 of A New Social History of Pharmacy & Pharmaceuticals Festival - Panel 10 "Medicine vs. Drugs: African Perspectives".
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 4: Invited Festival Talk "Vaccines & Epidemics: Successes & Crises from Smallpox to COVID-19”.
Join us for Day 5 of A New Social History of Pharmacy & Pharmaceuticals Festival - Invited Book Talk "Taming Cannabis: French Pharmacy, Cannabis, and Exotic Drugs".
Join us for A New Social History of Pharmacy & Pharmaceuticals Festival - Day 5: Panel 11 "Advertising Drugs and Pharmacy".
Guest speaker: Andrea Ens, Purdue University. This presentation outlines Canadian and American practitioners’ use of LSD, mescaline, and peyote in psychedelic conversion therapies during the postwar period. Such programs in both countries drew from widespread psychiatric faith in psychoanalysis and pharmacology in changing patient behavior, as well as shared Cold War-era cultural anxieties about sex, gender, and national security that negatively associated same-gender attraction with Communism, criminality, and psychopathy.
Guest speaker: Joanna Kempner, Rutgers University. Federal regulations mandate that investigators limit their clinical trials to pre-approved, standardized drugs to assure reliable results. Sometimes, however, unauthorized investigators) develop therapeutic protocols for the use of drugs in the underground, beyond the reach of federal regulators. This presentation investigates how unauthorized investigators engaged in “collective experimentation” standardize drugs given the difficulty of obtaining “laboratory-grade” pharmaceuticals by drawing on a case study of Clusterbusters.